SNOMED CT Editorial Advisory Group

Page tree



Date

2020-06-02

Time:

1900-2030 UTC

1200-1330 PDT

Zoom Meeting Details

Topic: SNOMED Editorial Advisory Group Conference Call
Time: Jun 2, 2020 12:00 PM Pacific Time (US and Canada)

Join from PC, Mac, Linux, iOS or Android:
https://snomed.zoom.us/j/97507109544?pwd=bFVCZmhYZ1I2S1JIK3U1b2VBWnBEUT09
Password: 614316

Meeting ID: 975 0710 9544

Password: 614316
International numbers available: https://snomed.zoom.us/u/daDj0O3t9

Or Skype for Business (Lync):
https://snomed.zoom.us/skype/97507109544



Attendees

Chair:

AG Members

Invitees:

 Farzaneh Ashrafi

Observers:

Anne Randorff Højen

Monica Harry

Suzanne Santamaria

Toni Morrison

Brian Carlsen



Apologies:

Meeting Files:


Meeting minutes:

The call recording is located here.


Objectives

  • Obtain consensus on agenda items

Discussion items

ItemDescriptionOwnerNotesAction
1Call to order and role call

Jim Case

Start recording!

 

2Conflicts of interest and agenda review

Jim Case

No conflicts noted 
3Antibody vs. ImmunoglobulinFarzaneh Ashrafi

Establishing definitions for terms representing Antibody and Immunoglobulin

Discussion:

While most people think of Immunoglobulins and antibodies as the same, there are substantive differences between them. General agreement that Immunoglobulins are a supertype of antibodies. Antibodies are conceived as circulating structures but there are non-circulating immunoglobulins as well.

While there are clear distinctions at a granular level, these two notions should not be disjoint. What we need in SNOMED CT is a clinically useful representation of these two concepts. The issue is how to properly represent Antibody (function) and immunoglobulin (structure). We need to make sure that whatever we choose, there must not be variability in the use of these to model other concepts. The vast majority of the time users will not make a distinction.

Is there a benefit in having a defined distinction between immunoglobulin and antibody other than stating one is a subtype of the other? Is antibody a Role? Is a gamma globulin the same as immunoglobulin?

Additional comments will be added to the JIRA ticket: SUBST-152 - Getting issue details... STATUS

  • Farzaneh Ashrafi will provide a link to the ticket an request additional comments from the EAG members.
4Report from Concept inactivation workgroupPaul Amos

The presentations will focus on 3 aspects:

  • A Review of the SNOMED CT historical associations
  • An update on progress to-date on developing documentation and raising some key issues
  • A proposed way forward for current and future work

Discussion:


5ECE updateBruce Goldberg
  • Approval for activating unapproved attribute, 410660005 |Aggravated by (attribute)| for modeling of disease exacerbations
  • Procedure complications:
    • Represent these as they are written out, i.e. do not assume that something is asserted to be a complication or sequela.
    • What does the assignment of a primitive sequela add, given that concepts will classify under other appropriate parents? 

Discussion:

Initial testing of the impact of inactivation of 362977000 |Sequela (disorder)| and replacement with 64572001 |Disease (disorder)| in concepts that had it assigned as the IS A parent results in a more complete set of subtypes classifying under 302049001 |Sequelae of disorders (disorder)| and 312087002 |Disorder following clinical procedure (disorder)|.

The availability of ECL was purported to be a more effective mechanism in identifying concepts that would be considered sequela or late effects than the manual assignment of a intermediate primitive concept.

Bruce Goldberg was asked to do more evaluation of the results of the inactivation of 362977000 |Sequela (disorder)|. If no issues remain, this concept will be inactivated in the Jan 2021 release. 

6Next meetingEAG

Doodle poll to be sent out for additional meeting in June

Discussion: